9 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Connecting Patients and Carers using wearable sensor technology (NIGHTINGALE)
Date du début: 1 nov. 2016, Date de fin: 31 oct. 2020,
Safest, reliable, individualised care of patients at-risk of deterioration needs patients themselves to play an active role in their care whenever possible: late detection or escalation of deterioration causes avoidable harms, and deaths. In this project we will challenge industry to develop robust monitoring and communications systems that connect patients, carers and health professionals, provid ...
Voir le projet
5
Participants partenaires
TERMINÉ
Autologous Stem Cell Seeded Tissue Engineered Trachea (TETRA)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
CLINICAL PROBLEM AND UNMET NEEDThere are 11,827 patients with severe structural airway disease in Europe. Even with the current standard of care, when hospitalised this group of patients has a 22% risk of dying. Patients are currently subjected to repeated surgical interventions (stent insertion) which have a high failure rate. Other therapeutic strategies under development include synthetic trac ...
Voir le projet
14
Participants partenaires
TERMINÉ
Does vascular endothelial growth factor gene therapy safely improve outcome in severe early-onset fetal growth restriction? (EVERREST)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2018,
Fetal growth restriction (FGR) globally occurs in 8% of pregnancies, is severe and early onset in 1:500 cases, affecting 11,000 babies annually in the EU. In most cases, reduced uterine blood flow restricts substrate delivery to the fetus causing growth to slow or cease. There is no treatment. Currently the fetus is delivered very preterm before fetal death or irreversible organ damage occurs. Aff ...
Voir le projet
10
Participants partenaires
TERMINÉ
EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (EEC)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with current treatment but there has been no improvement in this proportion for 25 years. Treatment is unsuccessful because chemotherapy fails to prevent the development of, or to effectively treat established, metastases. In addition, of the 600 new cases of ES o ...
Voir le projet
21
Participants partenaires
TERMINÉ
Adoptive engineered T cell Trials to Achieve Cancer Killing (ATTACK)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2017,
The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials ...
Voir le projet
16
Participants partenaires
TERMINÉ
Interferon-beta treatment of acute respiratory distress syndrome (ARDS) (TRAUMAKINE)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2016,
This application aims at a European marketing application for an orphan indication of the biopharmaceutical interferon-beta (IFN-beta) (EU3/07/505), to treat acute lunge injury (ALI) and acute respiratory distress syndrome (ARDS). Despite the much improved mechanical ventilation techniques and improved supportive therapies, ARDS kills 35-40 % of the 175.000 annual European patients. This condition ...
Voir le projet
5
Participants partenaires
TERMINÉ
Biopharmaceutical therapy for treatment of Primary Hyperoxaluria (ELIMOX)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2016,
"Interest in the use of naturally occurring human gut bacteria as pharmaceutical drugs has increased as knowledge about the human microbiota and its role in health and disease has advanced.The ELIMOX project proposes to develop a new drug from Oxalobacter formigenes, an anaerobic bacterium whose only carbon source is oxalate, for the treatment of primary hyperoxaluria (PH). PH is a rare and life-t ...
Voir le projet
12
Participants partenaires
TERMINÉ
Rapid Identification of Respiratory Tract Infections (RID-RTI)
Date du début: 1 juil. 2012, Date de fin: 31 déc. 2015,
Respiratory Tract Infections (RTIs) are caused by a variety of bacterial, viral, fungal and other pathogens. RTIs are major causes of morbidity and mortality in adults and children worldwide causing millions of deaths each year. RTIs affecting the lung parenchyma (pneumonia) can be classified into three main categories: Community Acquired Pneumonia (CAP); Hospital Acquired Pneumonia (HAP) which in ...
Voir le projet
6
Participants partenaires
TERMINÉ
Coordinating resources to assess and improve health status of migrants from Latin America (COHEMI)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2013,
"European health systems are committed to meeting the challenge of understanding the needs of migrant populations and adapting their services to meet these needs. The difficulties inextricably linked to this challenge are caused by the complexity of migration patterns and the differences between migrant population across EU countries. At present, the limited available data show that attempts to in ...
Voir le projet